Myopathies related to systemic sclerosis: a case–control study of associated clinical and immunological features

References

• Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003;2:152–7.
   PubMed Web of Science ®Google Scholar
• Servettaz A, Agard C, Tamby MC, Guilpain P, Guillevin L, Mouthon L. [Systemic sclerosis: pathophysiology of a multifaceted disease], in French. Presse Med 2006;35:1903–15.
   PubMedGoogle Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437–44.
   PubMed Web of Science ®Google Scholar
• Medsger TA Jr, Rodnan GP, Moossy J, Vester JW. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968;11:554–68.
   PubMedGoogle Scholar
• Thompson JM, Bluestone R, Bywaters EGL, Dorling J, Johnson M. Skeletal muscle involvement in systemic sclerosis. Ann Rheum Dis 1969;28:281–8.
   PubMedGoogle Scholar
• Clements PJ, Furst DE, Campion DS, Bohan A, Harris R, Levy J, Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 1978;21:62–71.
   PubMed Web of Science ®Google Scholar
• West SG, Killian PJ, Lawless OJ. Association of myositis and myocarditis in progressive systemic sclerosis. Arthritis Rheum 1981;24:662–8.
   PubMed Web of Science ®Google Scholar
• Hausmanowa-Petrusewicz I, Jablonska S, Blaszczyk M, Matz B. Electromyographic findings in various forms of progressive systemic sclerosis. Arthritis Rheum 1982;25:61–5.
   PubMedGoogle Scholar
• Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993;125:194–203.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 2005;24:99–102.
   PubMed Web of Science ®Google Scholar
• Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009;68:1474–7.
   PubMed Web of Science ®Google Scholar
• Ranque B, Authier FJ, Berezne A, Guillevin L, Mouthon L. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci 2007;1108:268–82.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, King LE Jr, Park JH. Muscle abnormalities in scleroderma. Rheum Dis Clin North Am 1996;22:783–96.
   PubMed Web of Science ®Google Scholar
• Ringel RA, Brick JE, Brick JF, Gutmann L, Riggs JE. Muscle involvement in the scleroderma syndromes. Arch Intern Med 1990;150:2550–2.
   PubMedGoogle Scholar
• D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428–40.
   PubMed Web of Science ®Google Scholar
• Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology (Oxford) 1999;38:397–400.
   PubMed Web of Science ®Google Scholar
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Medsger TA Jr.. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–6.
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754–63.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218–21.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Vignaux O, Arnaud L, Puechal X, Pavy S, Duboc D, Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65:249–52.
   PubMed Web of Science ®Google Scholar
• Steen V. The heart in systemic sclerosis. Curr Rheumatol Rep 2004;6:137–40.
   PubMedGoogle Scholar
• Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006;45(Suppl 4): iv14–17.
   PubMedGoogle Scholar
• Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008;20:697–702.
   PubMedGoogle Scholar
• Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878–84.
   PubMed Web of Science ®Google Scholar
• Russell ML, Hanna WM. Ultrastructure of muscle microvasculature in progressive systemic sclerosis: relation to clinical weakness. J Rheumatol 1983;10:741–7.
   PubMed Web of Science ®Google Scholar
• Scarpelli M, Montironi R, Tulli D, Sisti S, Matera G, Magi Galluzzi C, Quantitative analysis of quadriceps muscle biopsy in systemic sclerosis. Pathol Res Pract 1992;188:603–6.
   PubMedGoogle Scholar
• Steen VD, Medsger TA Jr.. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613–19.
   PubMed Web of Science ®Google Scholar
• DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983–9.
   PubMed Web of Science ®Google Scholar
• Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998;17:48–54.
   PubMed Web of Science ®Google Scholar
• Jablonska S, Blaszczyk M. Scleromyositis: a scleroderma/polymyositis overlap syndrome. Clin Rheumatol 1998;17(6):465–7.
   PubMedGoogle Scholar
• Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211–17.
   PubMed Web of Science ®Google Scholar